ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Population pharmacokinetic model for meropenem in pediatric patients: a systematic review.Frontiers in microbiology · 2026Pooled it
- Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.Clinical pharmacokinetics · 2022Pooled it
- Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.Clinical pharmacokinetics · 2020Pooled it
- Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review.Frontiers in pediatrics · 2020Pooled it
- Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.Antimicrobial agents and chemotherapy · 2026Observational
- Population pharmacokinetics and safety of continuous oxacillin in preterm and term neonates and infants.Antimicrobial agents and chemotherapy · 2026Article
- Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Can a population pharmacokinetics model built on intermittent infusions accurately predict meropenem concentrations in children receiving continuous infusions?British journal of clinical pharmacology · 2026Article
- Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.The Lancet regional health. Western Pacific · 2025Review
- Variability in Meropenem Distribution and Clearance in Children with Sepsis: Population-Based Pharmacokinetics with Assessment of Renal Biomarkers.Clinical pharmacokinetics · 2025Article
- A Real-Life Study of Prolonged Meropenem Infusion in Neonates and Children Admitted to Intensive Care Units: Are Three Hours Long Enough?Journal of clinical medicine · 2025Article
- Dosage Optimization Using Physiologically Based Pharmacokinetic Modeling for Pediatric Patients with Renal Impairment: A Case Study of Meropenem.AAPS PharmSciTech · 2025Article
- Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.The Journal of antimicrobial chemotherapy · 2024Article
- How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children.Antimicrobial agents and chemotherapy · 2024Article
- Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2024Article
- Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?The Journal of antimicrobial chemotherapy · 2022Article
- C/MIC > 4: A Potential Instrument to Predict the Efficacy of MeropenemAntibiotics (Basel, Switzerland) · 2022Article
- Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.Infectious diseases and therapy · 2022Article
- Beta-Lactams Therapeutic Monitoring in Septic Children-What Target Are We Aiming for? A Scoping Review.Frontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to describe the population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill children.
methodsThe study involved a retrospective medical record review from a 189-bed, freestanding children's tertiary care teaching hospital of patients ages 1 to 9 years who received meropenem with concurrent therapeutic drug monitoring.
resultsThere were 9 patients ages 1 to 9 years (mean age, 3.1 ± 2.9 years) with a mean weight of 17.1 ± 11.9 kg who met the inclusion/exclusion criteria and were included in the pharmacokinetic analysis. Meropenem concentrations were best described by a 2-compartment model with first-order elimination, with an
conclusionThese data suggest the reference dosage regimens for meropenem (20-40 mg/kg per dose every 8 hours) do not meet an appropriate pharmacodynamic target attainment in critically ill children ages 1 to 9 years. Based on these data, only the 3- to 4-hour prolonged infusion and 24-hour continuous infusion regimens were able to achieve an optimal probability of target attainment against all susceptible Gram-negative bacteria in critically ill children for 40%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.